ANAVEX LIFE SCIENCES CORP. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
ANAVEX LIFE SCIENCES CORP. (AVXL) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $2.61 million for the 12-month period ending 2014-09-30, per its 10-K filed 2016-12-14.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2016-12-14
- ANAVEX LIFE SCIENCES CORP. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2014 was $2.61M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month as first filed |
|---|---|---|---|---|
| 2014-09-30 | $2.61M 10-K · filed 2016-12-14 | $4.01M 10-K · filed 2014-12-29 | ||
| 2014-06-30 | $4.01M 10-Q · filed 2014-08-13 | |||
| 2014-03-31 | $4.01M 10-Q/A · filed 2014-05-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |